Cytotoxic drug induced nausea and vomiting is one of the most notorious problems associated with the chemotherapy of malignant disease. The classical experiments of Borison and Wang (1953) group, is sometimes effective even against 'low dose' cisplatin-induced vomiting.
High dose metoclopramide provided the impetus for many of the current studies because of its dramatic effect against cisplatinum induced vomiting. In the past 5 years modifications of the technique of delivery of metoclopramide have been followed from pharmacological studies in the UK and currently recommended practice is to give bolus plus continuous infusion therapy either alone or in combination with a corticosteroid.
The first reports of the value of corticosteroids against cytotoxic vomiting were produced by Cassileth who demonstrated the activity of dexamethasone. The mechanism of action of glucocorticoids is uncertain but they appear to be valuable additional compounds for combination anti-emetic therapy, particularly with high dose metoclopramide. Often benzodiazepines are used in combination and lorazepam is currently the most widely selected compound. Benzodiazepines may well affect the vomiting reflex by depressing higher cerebral centres and again may be most usefully employed in combination anti-emetic therapy. The development of combination anti-emetic therapy, however, carries its own dangers with the problems of drug interactions, not only between the anti-emetics themselves but between the antiemetics and cytotoxic agents either by direct interaction or more likely by altering the pharmacokinetics of the cytotoxic drugs.
The problem of anticipatory emesis is closely correlated with lack of good anti-emetic control with initial courses of chemotherapy. Morrow (1984) has identified a number of factors important in developing anticipatory nausea and vomiting including severity of post-chemotherapy vomiting, duration of nausea and number of courses of therapy with poorly controlled emesis. Recommendations have been made to reduce associated trigger factors such as having follow-up clinics in a different area to the treatment area and reducing distinctive features of treatment sites such as avoidance of strong-smelling cleaning fluids or air fresheners. The use of relaxation techniques and behaviour modification may also be very beneficial in some patients but are time-consuming and require experienced staff. The best method to prevent anticipatory problems is, however, good initial anti-emetic control and the early recognition of a developing problem in which context the use of benzodiazepines providing shortterm memory loss and sedation may be very beneficial.
Recent developments, both in new anti-emetics and better ways of using the existing ones, lead us to cautious optimism that nausea and vomiting due to cancer chemotherapy can be reduced substantially with considerable benefit to the patient.
